May 10, 2023 PR-M05-23-02
Milan, Italy - One year after the launch of the International Network for Biocatalysis, an innovative scientific platform for the study and development of new industrial applications of biocatalysis, Olon, the Biocatalysis research group from the University of Amsterdam’s Van ‘t Hoff Institute for Molecular Sciences HIMSand Biosphere jointly present the results obtained and announce that their cooperation has achieved the goal of developing a new production process through the engineering of the target enzyme, which has given extremely positive conversion results.
The effectiveness of the enzyme in the conversion of ketoacid to the corresponded unnatural aminoacid useful as key starting material for the production of an Active Pharmaceutical Ingredient, was substantiated by the significant metrics measuring complete conversion; the supporting data are: target minimum enantiomeric purity required 99.7%, enantiomeric purity obtained > 99.9%.
The research project followed a virtuous model of collaboration between Olon Group, the HIMS-Biocat group led by Prof. Francesco Mutti, who has pioneered ground-breaking research in enzyme engineering and the use of enzymes for performing novel, sustainable and “green” chemical reactions, and Biosphere, an Italian SME specialized in fermentation and industrial biotechnology. The first phase of the research focused on the selection of the enzyme and its engineering to obtain the best yield and selectivity in the reductive amination reaction. Once the ad hoc optimized enzyme was obtained, the second phase took the form of developing the enzyme production process by fermentation. Now, the project is in the final phase which foresees the completion of the production process on an industrial scale.
The partnership, which will be continued in the future with other research projects, brings together some of the most advanced expertise in the field of biocatalysis from both academic and industrial spheres, to implement large-scale biocatalysis as an industrial technology used within its production facilities in Italy and around the world.
Bioconversion is the transformation of a substrate, catalysed by an either free or immobilized enzyme, obtained from cellular cultures followed by different type of purification depending of the grade of enzyme needed for the specific process. New biocatalysts and biocatalytic systems can foster more sustainable and efficient synthesis of organic molecules that are relevant for the chemical industry, as well as to address fundamental questions of bioorganic chemistry and biochemistry.
The international network was created with the objective to launch large-scale biocatalysis as an industrial technology used within Olon production facilities in Italy and around the world. The partnership, bringing together some of the most advanced expertise in the field of biocatalysis from both academic and industrial spheres, unites the Olon Group, Biosphere — an Italian SME specialised in fermentation and industrial biotechnology — and the Biocatalysis Group of the Van't Hoff Institute for Molecular Sciences (HIMS-Biocat) at the University of Amsterdam (UvA). The HIMS-Biocat group, headed by Prof. Francesco Mutti, has pioneered ground-breaking research in the area of enzyme engineering and the use of enzymes for performing novel, sustainable and “green” chemical reactions.
www.olonspa.com / firstname.lastname@example.org
email@example.com – mobile 338.6674289
Biosphere is an Italian SME operating in the field of industrial biotechnology, with a focus on the development and scale-up of fermentation processes for the production of different biomolecules. Biosphere offers R&D services for the development and scale-up of biotechnological processes, from laboratory to pilot and pre-industrial scale, for recombinant protein and metabolites generation in bacteria and yeasts. The company also provides a qualified contract manufacturing service for the production of microbial biomass, enzymes and metabolites. The company’s own research and innovation activities are focused on the development of new processes, based on fermentation, for the valorization and re-use of by-products of the agro-food industry and the production of bio-based molecules and materials.
www.biospheresrl.com / firstname.lastname@example.org
email@example.com – tel 0543.444597
The van ’t Hoff Institute for Molecular Sciences (HIMS) at the University of Amsterdam (UvA) is organized in four complementary research themes: Synthesis & Catalysis, Analytical Chemistry, Computational Chemistry and Molecular Photonics, which provide a unique synergy for designing, creating, characterizing and understanding molecular systems to address important societal and industrial challenges. The Biocatalysis Group is part of the research theme Synthesis & Catalysis (SC) that focuses on the development of sustainable technologies that will enable to carry out chemical transformations in a more efficient manner. In this context, the Biocatalysis group carries out cutting-edge research at the interface between the chemical and the biological sciences. The research focuses on: 1) fundamental studies of enzyme catalysis and mechanisms; 2) engineering of enzymes to improve existing activities or create new activities or improve stability under industrially relevant conditions; 3) the development of novel biocatalytic systems (e.g., cascades) for the sustainable manufacture of chemical products in batch or continuous flow systems; 4) biocatalysis in vivo; 5) bio-photocatalysis and bio-electrocatalysis.
https://hims.uva.nl/ / http://www.hims-biocat.eu/
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.